Novel antimicrobial compound and use thereof

Abstract

The present invention relates to: coralmycin A and B, which are novel compounds exhibiting antimicrobial activity, an isomer thereof, a derivative thereof or a pharmaceutically acceptable salt thereof; a microorganism of the genus Corallococcus producing the same; and an antimicrobial use thereof. The coralmycin A and B have very strong antimicrobial activity against antibiotic-resistant bacteria such as MRSA, QRSA, VRE, VISA, etc.; Acinetobacter baumannii, which is a multidrug-resistant microorganism; and also against gram-positive microorganisms and gram-negative microorganisms. Therefore, the present invention can be very useful for prevention, treatment and alleviation of various microbial infections, and thus can be widely applied to the medical supply, quasi-drug, food, and feed industries.

What is claimed is: 
     
         1 . A compound represented by the following Formula 1 or 2, an isomer thereof, or a pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
       
     
     
         2 . A  Corallococcus coralloides  microorganism having an antimicrobial activity, wherein the microorganism produces the compound represented by Formula 1 or Formula 2 of  claim 1 , an isomer thereof, or a pharmaceutically acceptable salt thereof. 
     
     
         3 . The microorganism of  claim 2 , wherein the microorganism is  Corallococcus coralloides  M23 deposited under the Accession Number KCTC12812BP. 
     
     
         4 . An antimicrobial composition comprising the compound represented by Formula 1 or Formula 2 of  claim 1 , an isomer thereof, a pharmaceutically acceptable salt thereof, the microorganism of  claim 2 , a spore of the microorganism, a culture broth of the microorganism, an extract of the microorganism, a fraction of the extract, or a mixture thereof. 
     
     
         5 . The antimicrobial composition of  claim 4 , wherein the composition has an antimicrobial activity against a gram-positive microorganism with or without antibiotic-resistance; or a gram-negative microorganism with or without antibiotic-resistance. 
     
     
         6 . The antimicrobial composition of  claim 5 , wherein the antibiotic is at least one selected from the group consisting of a penicillin antibiotic, a methicillin antibiotic, a quinolone antibiotic, a vancomycin antibiotic, a carbapenem antibiotic, and an aminoglycoside antibiotic. 
     
     
         7 . The antimicrobial composition of  claim 5 , wherein the gram-positive microorganism is a microorganism of the genus  Staphylococcus,  the genus  Bacillus,  the genus  Streptococcus,  or the genus  Enterococcus;  and the gram-negative microorganism is a microorganism of the genus  Salmonella,  the genus  Acinetobacter,  the genus  Escherichia,  the genus  Pseudomonas,  or the genus  Klebsiella.    
     
     
         8 . The antimicrobial composition of  claim 5 , wherein the gram-positive microorganism is  Staphylococcus aureus,  methicillin-resistant  Staphylococcus aureus  (MRSA), quinolone-resistant  Staphylococcus aureus  (QRSA), vancomycin resistant  Enterococcus  (VRE), vancomycin intermediate-resistant  S. aureus  (VISA),  Bacillus subtilis, Bacillus cereus, Streptococcus pneumoniae, Enterococcus faecalis,  or  Staphylococcus epidermidis;  and the gram-negative microorganism is  Salmonella typhimurium, Acinetobacter calcoaceticus, Acinetobacter baumanii, E. coli, Pseudomonas aeruginosa, Klebsiella aerogenes,  or  Klebsiella pnemoniae.    
     
     
         9 . The antimicrobial composition of  claim 4 , wherein the composition is a pharmaceutical composition, a quasi-drug composition, a food composition, or a feed composition for livestock or fish. 
     
     
         10 . The antimicrobial composition of  claim 9 , wherein the pharmaceutical composition is for preventing or treating at least one disease selected from the group consisting of (i) to (iii) below:
 (i) pyogenic infection;   (ii) food poisoning; and   (iii) bacteremia, sepsis, urinary tract infection, pneumonia, pleural empyema, tympanitis, mastoiditis, meningitis, osteomyelitis, arthritis, peritonitis, pericarditis, cellulitis, typhus, and acute gastroenteritis.   
     
     
         11 . The antimicrobial composition of  claim 9 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier. 
     
     
         12 . A method for treating at least one disease selected from the group consisting of (i) to (iii) below, comprising administering the composition of  claim 4  to a subject in need thereof:
 (i) pyogenic infection; 
 (ii) food poisoning; and 
 (iii) bacteremia, sepsis, urinary tract infection, pneumonia, pleural empyema, tympanitis, mastoiditis, meningitis, osteomyelitis, arthritis, peritonitis, pericarditis, cellulitis, typhus, and acute gastroenteritis. 
 
     
     
         13 . A method for preparing the compound represented by Formula 1 or Formula 2 of  claim 1 , an isomer thereof, or a pharmaceutically acceptable salt thereof, comprising:
 (a) culturing a  Corallococcus coralloides  microorganism;   (b) extracting a culture solution or fruiting body of the microorganism obtained in step (a); and   (c) isolating the compound represented by Formula 1 or Formula 2 of  claim 1 , an isomer thereof, or pharmaceutically acceptable salt thereof, from the extract obtained in step (b)